

YEAR	NO.	MANUSCRIPT	TRIAL
2022	1	Mercieca-Bebber, Rebecca PhD*; Eggins, Renee MBIostat†; Brown, Killian MPhil‡; Gebski, Val J. MStat‡; Brewer, Kate BMedMath‡; Lai, Lenna B.FoodNutrSc(Hons)‡; Bailey, Lisa BAppSc‡; Solomon, Michael J. MBCh, BAO, MSc, DMedSc, DMed, FRCSI, FRACS, LRCPI‡; Lumley, John W. MBBS, FRACS§; Hewett, Peter MBBS, FRACS¶; Clouston, Andrew D. MBBS, PhD, FRCPA ; Wilson, Kate MPH‡; Hague, Wendy MBBS, PhD, MBA‡; Hayes, Julian MBChB**; White, Stephen FRACS††; Morgan, Matt MSurg‡‡; Simes, John BSc (Med), MBBS, SM, FRACP, MD‡; Stevenson, Andrew R. L. MBBS, FRACS, FASCRS (Hon)§§ Patient-Reported Bowel, Urinary and Sexual Outcomes After Laparoscopic-Assisted Resection or Open Resection for Rectal Cancer, <i>Annals of Surgery</i> : February 15, 2022 - Volume - Issue - doi: 10.1097/SLA.0000000000005412	ALaCart
2022	2	Mercieca-Bebber, R., Barnes, E.H., Wilson, K. <i>et al.</i> Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: a randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinoma. <i>BMC Cancer</i> 22, 276 (2022). https://doi.org/10.1186/s12885-022-09270-4	DOCTOR
2022	3	Vatandoust, S., Wattchow, D., Sposato, L. <i>et al.</i> A longitudinal cohort study of watch and wait in complete clinical responders after chemo-radiotherapy for localised rectal cancer: study protocol. <i>BMC Cancer</i> 22, 222 (2022). https://doi.org/10.1186/s12885-022-09304-x	RENO
2021	4	Blinman P, Martin A, Jefford M, Goldstein D, Boadle D, Morris M, <i>et al.</i> Patients' preferences for 3 months vs 6 months of adjuvant chemotherapy for colon cancer. <i>JNCI Cancer Spectr.</i> 2021;5(1):pkaa107.	SCOT
2021	5	Law CK, Stevenson ARL, Solomon M, Hague W, Wilson K, Simes JR, <i>et al.</i> Healthcare costs of laparoscopic versus open surgery for rectal cancer patients in the first 12 months: A secondary endpoint analysis of the Australasian Laparoscopic Cancer of the Rectum Trial (ALaCaRT). <i>Ann Surg Oncol.</i> 2021.	A La CaRT
2021	6	Keane C R, O'Grady G, Bissett I P, Hayes J, Hulme-Moir M, Elington T W, Solomon M J, Lumley J W, Simes J, Stevenson A R L, Functional Outcome of Laparoscopic Assisted Resection vs Open Resection of Rectal Cancer: A secondary analysis of the Australasian Laparoscopic Cancer of the Rectum Trial. PubMed PMID: 34775413 DOI:10.1097/DCR.0000000000002166, November 2021	A La CaRT
2021	7	Loree JM, Dowers A, Tu D, Jonker DJ, Ederstein DE, Quinn T, Holtrup T, Price T, Zalcberg JR, Moore MJ, Karapetis CS, O'Callaghan CJ, Waring P, Kennecke HF, Hamilton SR, Kopetz S. Expanded Low Allele Frequency RAS and BRAF V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial. <i>Clin Cancer Res.</i> 2021 Jan 1;27(1):52-59. doi: 10.1158/1078-0432.CCR-20-2710. Epub 2020 Oct 21. PMID: 33087330; PMCID: PMC7795657	CO.17
2021	8	Jiang D, Hveem TS, Glaire M, Church DN, Kerr DJ, Yang L, Danielsen HE. Automated assessment of CD8+ T-lymphocytes and stroma fractions complement conventional staging of colorectal cancer. <i>EBioMedicine.</i> 2021 Aug 30;71:103547. doi: 10.1016/j.ebiom.2021.103547. Epub ahead of print. PMID: 34479131.	QUASAR
2021	9	Palles C, Fotheringham S, Chegwidden L, Lucas M, Kerr R, Mozolowski G, Rosmarin D, Taylor JC, Tomlinson I, Kerr D. An Evaluation of the Diagnostic Accuracy of a Panel of Variants in DPYD and a Single Variant in ENOSF1 for Predicting Common Capecitabine Related Toxicities. <i>Cancers (Basel).</i> 2021 Mar 24;13(7):1497. doi: 10.3390/cancers13071497. PMID: 33805100; PMCID: PMC8037940.	QUASAR
2021	10	Oar A, Lee M, Le H, Wilson K, Aiken C, Chantrill L, Simes J, Nguyen N, Barbour A, Samra J, Sjoquist KM, Moore A, Espinoza D, Gebski V, Yip S, Chu J, Kneebone A, Goldstein D, AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer, <i>BMC Cancer</i> volume 21, August 2021.	MASTERPLAN
2021	11	Siu D, Tebbutt N, Chantrill L, Karapetis C, Steer C, Wilson K, Espinoza D, Bailey L, Yip S, Cuff J, Pavlakis N, Thavaneswaran S, Briscoe K, Srivastav R, Shannon J, Segelov E, Tie J, Caird S, Francesconi A, Price T, Wuttke M, Ladwa R, Sjoquist K, Burge M, MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG). <i>BMC Cancer.</i> August 2021.	MONARCC
2021	12	Dunn C, Hong W, Gibbs P, Ackland S, Sjoquist K, Tebbutt N, Price T, Burge M, Personalizing First-Line Systemic Therapy in Metastatic Colorectal Cancer: Is There a Role for Initial Low-Intensity Therapy in 2021 and Beyond? A Perspective From Members of the Australasian Gastrointestinal Trials Group, <i>Clinical Colorectal Cancer</i> , May 2021	Review
2021	13	Ping Ng S, Leong T, Role of Radiation Therapy in Gastric Cancer, <i>Ann Surg Oncol</i> , March 2021.	TOPGEAR
2021	14	Mariadason JM, Lau DK, Luk IY, Jenkins LJ, Martin A, Williams DS, Schoffer KL, Chionh F, Buchert M, Sjoquist K, Boussioutas A, Hayes SA, Ernst M, Weickhardt AJ, Pavlakis N and Tebbutt NC, Rapid resistance of FGFR-driven gastric cancers to regorafenib and targeted FGFR inhibitors can be overcome by parallel inhibition of MEK. <i>Molecular Cancer Therapeutics</i> , February 2021.	INTEGRATE II
2020	15	Fontana E, Nyamundanda G, Cunningham D, Tu D, Cheang MCU, Jonker DJ, Siu LL, Sclafani F, Eason K, Ragulan C, Bali MA, Hulkki-Wilson S, Loree JM, Waring PM, Giordano M, Lawrence P, Rodrigues DN, Begum R, Shapiro JD, Price TJ, Cremolini C, Starling N, Pietrantonio F, Trusolino L, O'Callaghan CJ, Sadanandam A. Intratumoral Transcriptome Heterogeneity Is Associated With Patient Prognosis and Sidedness in Patients With Colorectal Cancer Treated With Anti-EGFR Therapy From the CO.20 Trial. <i>JCO Precis Oncol.</i> 2020 Sep 29;4:PO.20.00050. doi: 10.1200/PO.20.00050. PMID: 33015526; PMCID: PMC7529528.	CO.20
2020	16	Law CK, Brewer K, Brown C, Wilson K, Bailey L, Hague W, Simes J, Stevenson A, Solomon M, Morton R, Return to work following laparoscopic-assisted resection or open resection for rectal cancer: Findings from ALaCaRT—Australasian Laparoscopic Cancer of the Rectum Trial, <i>Cancer Medicine</i> , December 2020.	A La CaRT
2020	17	Schmoll H-J, Stein A, Van Cutsem E, Price T, Hofheinz RD, Nordlinger B, Daisne J-F, Janssens J, Brenner B, Schmidt P, Reinel H, Hollerbach S, Caca K, Fauth F, Hannig CV, Zalcberg J, Tebbutt N, Mauer ME, Marreaud S, Lutz MP, Haustermans K, Pre- and postoperative capecitabine without or with oxaliplatin in locally advanced rectal cancer. PETACC 6 trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD, <i>J Clin Oncol</i> 2020; September 2020.	PETACC-6
2020	18	Segelov E, Prenen H, Day D, Macintyre R, Jye Foo EM, Ali R, Wang Q, Wei X, de Lima Lopes Jr G, Ding K, Chen G, Kuang Chia JW, Chong Toh H, on behalf of the ASCOLT Investigators, Impact of the COVID-19 Epidemic on a Pan-Asian Academic Oncology Clinical Trial; <i>J Global Oncology</i> 2020; April.	ASCOLT

YEAR	NO.	MANUSCRIPT	TRIAL
2020	19	Rao S, Sclafani F, Eng C, Adams RA, Guren MG, Sebag-Montefiore D, Benson A, Bryant A, Peckitt C, Segelov E, Roy A, Seymour MT, Welch J, Saunders MP, Muirhead R, O'Dwyer P, Bridgewater J, Bhide S, Glynne-Jones R, Arnold D, Cunningham D, International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAACT, <i>J Clin Oncol</i> 38, 2020; September	InterAACT
2020	20	Roy A, Shapiro J, Burge M, Karapetis C, Pavlakis N, Segelov E, Chau I, Lordick F, Chen LT, Barbour A, Tebbutt N, Price T, Management of early-stage gastro-esophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty; <i>Expert Review of Anticancer Therapy</i> 2020 Apr;20(4):305-324.	Review
2020	21	Gronchi A, Bonvalot S, Velasco AP, Kotasek D, Rutkowski P, Hohenberger P, Fumagalli E, Judson I, Italiano A, Gelderblom HJ, Van Coevorden F, Penel N, Kopp HG, Duffaud F, Goldstein D, Broto JM, Wardelmann E, Marreaud S, Smithers M, Cesne AL, Zaffaroni F, Litiere S, Blay JY, Casali PG, Quality of Surgery and Outcome in Localised Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomised Clinical Trial of Adjuvant Imatinib, <i>JAMA Surgery</i> 2020; April.	ALT-GIST
2020	22	Barbour AP, Samra JS, Haghghi KS, Donoghoe MW, Burge M, Harris MT, Chua YJ, Mitchell J, O'Rourke N, Chan H, GebSKI VJ, Gananadha S, Croagh DG, Kench JG, Goldstein D, The AGITG GAP Study: A Phase II Study of Perioperative Gemcitabine and Nab-Paclitaxel for Resectable Pancreas Cancer, <i>Ann Surg Oncol</i> 2020; January.	GAP
2020	23	Barbour AP, Walpole ET, Mai GT, Barnes EH, Watson DI, Ackland SP, Martin JM, Burge M, Finch R, Karapetis CS, Shannon J, Nott LM, Varma S, Marx G, Falk GL, GebSKI V, Oostendorp M, Wilson K, Thomas J, Lampe G, Zalcbberg JR, Simes J, Smithers BM, Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II trial, <i>Ann Oncology</i> 2020; January.	DOCTOR
2020	24	Lau DK, Burge M, Roy A, Chau I, Haller DG, Shapiro JD, Peeters M, Pavlakis N, Karapetis CS, Tebbutt NC, Segelov E, Price TJ, Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019. <i>Expert Rev Anticancer Ther.</i> 2020 Apr;20(4):251-270. doi: 10.1080/14737140.2020.1744439. Epub 2020 Apr 6.	Review
2019	25	Wells JC, Tu D, Siu LL, Shapiro JD, Jonker DJ, Karapetis C, et al. Outcomes of older patients (>= 70 Years) treated with targeted therapy in metastatic chemorefractory colorectal cancer: retrospective analysis of NCIC CTG CO.17 and CO.20. <i>Clin Colorectal Cancer.</i> 2019;18(1):e140-e9.	CO.17
2019	26	Jameson MB, Gormly K, Espinoza D, Hague W, Asghari G, Jeffery GM, Price TJ, Karapetis CS, Arendse M, Armstrong J, Childs J, Frizelle FA, Ngan S, Stevenson A, Oostendorp M, Ackland SP, SPAR - a randomised, placebo-controlled phase II trial of simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer: an AGITG clinical trial, <i>BMC Cancer.</i> 2019 Dec 17;19(1):1229. doi: 10.1186/s12885-019-6405-7.	SPAR
2019	27	Oar A, Lee M, Le H, Hruby G, Dalfts R, Pryor D, Lee D, Chu J, Holloway L, Briggs A, Barbour A, Chander S, Ng SP, Samra J, Shakeshaft J, Goldstein D, Nguyen N, Goodman KA, Chang DT, Kneebone A, Australasian Gastrointestinal Trials Group (AGITG) and Trans-Tasman Radiation Oncology Group (TROG) Guidelines for Pancreatic Stereotactic Body Radiation Therapy (SBRT). <i>Practical Radiation Oncology</i> November 2019.	MASTERPLAN
2019	28	Chua YJ, Pavlakis N, Sjoquist K, Martin AJ, Tsobanis E, Yip S, Bang Y-J, Alcindor T, O'callaghan CJ, Bekaii-Saab TS, Grothey A, Chen L-T, Simes J, Zalcbberg JR, Goldstein D, Komatsu Y, Machida N, Esaki T, Hara H, Shitara K, Randomised Phase 3 Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC) - INTEGRATE II. <i>Ann Oncology</i> 2019; 30; October.	INTEGRATE II
2019	29	Rico GT, Price T, Tebbutt N, Hardingham J, Lee C, Buizen L, Wilson K, GebSKI V, Townsend A, Right or left primary site of colorectal cancer: outcomes from the molecular analysis of the AGITG MAX trial, <i>Clinical Colorectal Cancer</i> (June 2019), doi: https://doi.org/10.1016/j.clcc.2018.12.002	MAX
2019	30	Stevenson A, Solomon M, Brown C, Lumley J, Hewett P, Clouston A, GebSKI V, Wilson K, Hague W, Simes J. Disease-free Survival and Local Recurrence After Laparoscopic-assisted Resection or Open Resection for Rectal Cancer: The Australasian Laparoscopic Cancer of the Rectum Randomised Clinical Trial. <i>Ann Surg</i> April 2019;269:596-602	A La CaRT
2018	31	Shepshelovich D, Townsend AR, Espin-Garcia O, Latifovic L, O'Callaghan CJ, Jonker DJ, Tu D, Chen E, Morgen E, Price TJ, Shapiro J, Siu LL, Kubo M, Dobrovic A, Ratain MJ, Xu W, Mushiroda T, Liu G. Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer. <i>Cancer Med.</i> 2018 Nov;7(11):5478-5487. doi: 10.1002/cam4.1819. Epub 2018 Oct 14. PMID: 30318772; PMCID: PMC6246957.	CO.20
2018	32	Domingo E, Camps C, Kaisaki PJ, Parsons MJ, Mouradov D, Pentony MM, Makino S, Palmieri M, Ward RL, Hawkins NJ, Gibbs P, Askautrud H, Oukrif D, Wang H, Wood J, Tomlinson E, Bark Y, Kaur K, Johnstone EC, Palles C, Church DN, Novelli M, Danielsen HE, Sherlock J, Kerr D, Kerr R, Sieber O, Taylor JC, Tomlinson I. Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series. <i>Lancet Gastroenterol Hepatol.</i> 2018 Sep;3(9):635-643. doi: 10.1016/S2468-1253(18)30117-1. Epub 2018 Jul 2. PMID: 30042065; PMCID: PMC6088509.	QUASAR
2018	33	Salem ME, Yin J, Weinberg BA, Renfro LA, Pederson LD, Maughan TS, Adams RA, Van Cutsem E, Falcone A, Tebbutt NC, Seymour MT, Díaz-Rubio E, Aranda E, Bokemeyer C, Heinemann V, Wasan H, de Gramont A, Grothey A, Shi Q, Sargent DJ, Marshall JL. Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database. <i>Eur J Cancer.</i> 2018 Nov;103:205-213. doi: 10.1016/j.ejca.2018.08.020. Epub 2018 Sep 27. PMID: 30268921.	MAX
2018	34	Kim SR, Song N, Yothers G, Gavin PG, Allegra CJ, Paik S, Pogue-Geile KL. Tumour sidedness and intrinsic subtypes in patients with stage II/III colon cancer: analysis of NSABP C-07 (NRG Oncology). <i>Br J Cancer.</i> 2018 Mar 6;118(5):629-633. doi: 10.1038/bjc.2017.448. Epub 2017 Dec 14. PMID: 29241223; PMCID: PMC5846062.	C-07
2018	35	Segelov E, Sieber O, Chia JWK, Williams DS. COX2 and HLA immunohistochemical (IHC) staining in colorectal tumour samples from patients participating in the ASCOLT clinical trial of adjuvant aspirin therapy. <i>J Clin Oncol.</i> 2018 Feb; 36 (4 suppl), 695	ASCOLT
2018	36	Mooi JK, Wirapati P, Asher R, Lee CK, Savas PS, Price TJ, Townsend A, Hardingham J, Buchanan D, Williams D, Tejpar S, Mariadason JM, Tebbutt NC. The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: Molecular analysis of the AGITG MAX clinical trial. <i>Ann Oncol.</i> 2018; Nov 1; 29(11):2240-2246. doi.org/10.1093/annonc/mdy410	MAX

YEAR	NO.	MANUSCRIPT	TRIAL
2018	37	Grothey A, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, Souglakos J, Shi Q, Kerr R, Labianca R, Meyerhardt JA, Vernerey D, Yamanaka T, Boukovinas I, Meyers JP, Renfro LA, Niedzwiecki D, Watanabe T, Torri V, Saunders M, Sargent DJ, Andre T, Iveson T. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer <i>N Engl J Med</i> . 2018 Mar 29;378(13):1177-1188.	IDEA (includes SCOT)
2018	38	Jonker DJ, Nott L, Yoshino T, Gill S, Shapiro J, Ohtsu A, Zalberg J, Vickers MM, Wei AC, Gao Y, Tebbutt NC, Markman B, Price T, Esaki T, Koski S, Hitron M, Li W, Li Y, Magoski NM, Li CJ, Simes J, Tu D, O'Callaghan CJ. Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial. <i>Lancet Gastroenterol Hepatol</i> , 2018 Apr; 3(4):263-270. doi: 10.1016/S2468-1253(18)30009-8. Epub 2018 Feb 1	CO.23
2018	39	Shapiro JD, Thavaneswaran S, Underhill CR, Robledo KP, Karapetis CS, Day FL, Nott LM, Jefford M, Chantrill LA, Pavlakis N, Tebbutt NC, Price TJ, Khasraw M, Van Hazel GA, Waring PM, Tejpar S, Simes J, GebSKI VJ, Desai J, Segelov E, Cetuximab alone or with irinotecan for resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type metastatic colorectal cancer: the AGITG randomised phase II ICECREAM study, <i>Clin Colorectal Cancer</i> 2018 Dec; 17(4):313-319. doi: 10.1016/j.clcc.2018.06.002. Epub 2018 Jun 8.	ICECREAM
2018	40	Tang M, Price TJ, Shapiro J, Gibbs P, Haller DG, Arnold D, Peeters M, Segelov E, Roy A, Tebbutt N, Pavlakis N, Karapetis C, Burge M. Adjuvant therapy for resected colon cancer 2017, including the idea analysis. <i>Expert Review of Anticancer Therapy</i> . 2018;18(4):339-349.	Review
2018	41	André T, Vernerey D, Mineur L, Bennouna J, Desrame J, Faroux R, Fratte S, Hug de Larauze M, Paget-Bailly S, Chibaudel B, Bez J, Dauba J, Louvet C, Lepere C, Dupuis O, Becouarn Y, Mabro M, Egreteau J, Bouche O, Deplanque G, Ychou M, Galais MP, Ghiringhelli F, Dourthe LM, Bachel JB, Khalil A, Bonnetain F, de Gramont A, Taieb J; for PRODIGE investigators, GERCOR, Fédération Française de Cancérologie Digestive, and UNICANCER. Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial. <i>J Clin Oncol</i> . 2018 May 20;36(15):1469-1477. doi: 10.1200/JCO.2017.76.0355. Epub 2018 Apr 5.	IDEA (includes SCOT)
2018	42	Iveson TJ, Kerr RS, Saunders MP, Cassidy J, Hollander NH, Tabernero J, Haydon A, Glimelius B, Harkin A, Allan K, McQueen J, Scudder C, Boyd KA, Briggs A, Waterston A, Medley L, Wilson C, Ellis R, Essapen S, Dhadda AS, Harrison M, Falk S, Raouf S, Rees C, Olesen RK, Propper D, Bridgewater J, Azzabi A, Farrugia D, Webb A, Cunningham D, Hickish T, Weaver A, Gollins S, Wasan HS, Paul J. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer: an international, randomised, phase 3, non-inferiority trial. <i>Lancet Oncol</i> . 2018 Apr;19(4):562-578. doi: 10.1016/S1470-2045(18)30093-7.	SCOT
2018	43	Leong T, Editorial - A CRITICAL period for chemoradiotherapy in gastric cancer. <i>Lancet Oncol</i> . 2018 May;19	TOPGEAR
2017	44	Casali PG, Zalberg J, Le Cesne A, Reichardt P, Blay JY, Lindner LH, Judson IR, Schoffski P, Leyvraz S, Italiano A, Grunwald V, Pousa AL, Kotasek D, Sleijfer S, Kerst JM, Rutkowski P, Fumagalli E, Hogendoorn P, Litiere S, Marreaud S, van der Graaf W, Gronchi A, Verweij J. Ten-year progression-free and overall survival in patients with unresectable or metastatic GI stromal tumors: long- term analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group intergroup phase III randomized trial on imatinib at two dose levels. <i>Journal of Clinical Oncology</i> 2017; 35(15): 1713–1720.	EORTC 62005
2017	45	Leong T, Smithers BM, Haustermans K, Michael M, GebSKI V, Miller D, Zalberg J, Boussioutas A, Findlay M, O'Connell RL, Verghis J, Willis D, Kron T, Crain M, Murray WK, Lordick F, Swallow C, Darling G, Simes J, Wong R. TOPGEAR: a randomized, phase III trial of perioperative ECF chemotherapy with or without preoperative chemoradiation for resectable gastric cancer: interim results from an international, intergroup trial of the AGITG, TROG, EORTC and CCTG. <i>Annals of Surgical Oncology</i> 2017; 24(8): 2252–2258.	TOPGEAR
2017	46	Martin AJ, Gibbs E, Sjoquist K, Pavlakis N, Simes J, Price T, Shannon J, Gill S, Jain V, Liu G, Kannourakis G, Kim YH, Kim JW, Goldstein D. Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. <i>Gastric Cancer</i> . Online 18 Aug 2017.	INTEGRATE
2017	47	Smyth EC, Wotherspoon A, Peckitt C, Gonzalez D, Hulkki-Wilson S, Eltahir Z, Fassan M, Ruge M, Valeri N, Okines A, Hewish M, Allum W, Stenning S, Nankivell M, Langley R, Cunningham D. Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial. <i>JAMA Oncol</i> . 2017 Sep 1;3(9):1197-1203. doi: 10.1001/jamaoncol.2016.6762. PMID: 28241187; PMCID: PMC5824280.	MAGIC
2017	48	McNamara MG, Bridgewater J, Lopes A, Wasan H, Malka D, Jensen LH, Okusaka T, Knox JJ, Wagner D, Cunningham D, Shannon J, Goldstein D, Moehler M, Bekaii-Saab T, Valle JW. 1Systemic therapy in younger and elderly patients with advanced biliary cancer: subanalysis of ABC-02 and twelve other prospective trials. <i>BMC Cancer</i> (2017) 17:262	TACTIC
2017	49	Segelov E, Lordick F, Goldstein D, Chantrill LA, Croagh D, Lawrence B, Arnold D, Chau I, Obermannova R, Price TJ. Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. <i>Expert Review of Anticancer Therapy</i> 2017; 17(10): 951–964.	Review
2017	50	Thavaneswaran S, Kok PS, Price T. Evaluating the addition of oxaliplatin to single agent fluoropyrimidine in the treatment of locally advanced rectal cancer: a systematic review and meta-analysis. <i>Expert Review of Anticancer Therapy</i> 2017; 17(10) 965–979.	Review
2017	51	Martinelli P, Carrillo-de Santa Pau E, Cox T, Sainz B Jr, Dusetti N, Greenhalf W, Rinaldi L, Costello E, Ghaneh P, Malats N, Büchler M, Pajic M, Biankin AV, Iovanna J, Neoptolemos J, Real FX. GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer. <i>Gut</i> . 2017 Sep;66(9):1665-1676. doi: 10.1136/gutjnl-2015-311256. Epub 2016 Jun 20. PMID: 27325420; PMCID: PMC5070637.	ESPAC-3
2017	52	Ansari N, Solomon MJ, Fisher RJ, Mackay J, Burmeister B, Ackland S, Heriot A, Joseph D, McLachlan S-A, McClure B, Ngan SY. Acute Adverse Events and Postoperative Complications in a Randomized Trial of Preoperative Short-course Radiotherapy Versus Long-course Chemoradiotherapy for T3 Adenocarcinoma of the Rectum: Trans-Tasman Radiation Oncology Group Trial (TROG 01.04). <i>Ann Surg</i> . 2017;265(5):882-888. doi:10.1097/SLA.0000000000001987	TROG 01.04
2016	53	Chandrasegaram MD, Chen JW, Price TJ, Zalberg J, Sjoquist K, Merrett ND. Advances in molecular pathology and treatment of periampullary cancers. <i>Pancreas</i> 2016; 45(1): 32-39.	Review
2016	54	Bridgewater J, Lopes H, Wasan H, Malka D, Jensen L, Okusaka T, Knox J, Wagner D, Cunningham D, Shannon J, Goldstein D, Moehler M, Bekaii-Saab T, McNamara MG, Valle JW. Prognostic factors for progression-free and overall survival in advanced biliary tract cancer, <i>Annals of Oncology</i> 27: 134–140, 2016	TACTIC

YEAR	NO.	MANUSCRIPT	TRIAL
2016	55	Ferraro D, Goldstein D, O'Connell RL, Zalberg JR, Sjoquist KM, Tebbutt NC, Grimison P, McLachlan S, Lipton LL, Vasey P, GebSKI VJ, Aiken C, Cronk M, Ng S, Karapetis CS, Shannon J. TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer. <i>Cancer Chemotherapy and Pharmacology</i> 2016; 78(2): 361–367.	TACTIC
2016	56	Franko J, Shi Q, Meyers JP, Maughan TS, Adams RA, Seymour MT, Saltz L, Punt CJA, Koopman M, Tournigand C, Tebbutt NC, Diaz- Rubio E, Souglakos J, Falcone A, Chibaudel B, Heinemann V, Moen J, De Gramont A, Sargent DJ, Grothey A. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. <i>Lancet Oncology</i> 2016; 17(12): 1709–1719.	ARCAD
2016	57	Gandy RC, Barbour AP, Samra J, Nikfarjam M, Haghghi K, Kench JG, Saxena P, Goldstein D. Refining the care of patients with pancreatic cancer: the AGITG Pancreatic Cancer Workshop consensus. <i>Medical Journal of Australia</i> 2016; 204(11): 419–422.	Review
2016	58	Gormly KL, Coscia C, Wells T, Tebbutt N, Harvey JA, Wilson K, Schmoll HJ, Price T. MRI rectal cancer in Australia and New Zealand: an audit from the PETACC-6 trial. <i>Journal of Medical Imaging and Radiation Oncology</i> 2016; 60(5): 607–615.	PETACC-6
2016	59	Hammel P, Huguet F, van Laethem JL, Goldstein D, Glimelius B, Artru P, Borbath I, Bouche O, Shannon J, Andre T, Mineur L, Chibaudel B, Bonnetain F, Louvet C. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. <i>JAMA</i> 2016; 315(17): 1844–1853.	LAP07
2016	60	Kerr RS, Love S, Segelov E, Johnstone E, Falcon B, Hewett P, Weaver A, Church D, Scudder C, Pearson S, Julier P, Pezzella F, Tomlinson I, Domingo E, Kerr DJ. Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> 2016; 17(11): 1543–1557.	QUASAR 2
2016	61	Liu G, Tu D, Lewis M, Cheng D, Sullivan LA, Chen Z, Morgen E, Simes J, Price TJ, Tebbutt NC, Shapiro JD, Jeffery GM, Mellor JD, Mikeska T, Virk S, Shepherd LE, Jonker DJ, O'Callaghan CJ, Zalberg JR, Karapetis CS, Dobrovic A. Fc-gamma receptor polymorphisms, cetuximab therapy, and survival in the NCIC CTG CO.17 trial of colorectal cancer. <i>Clinical Cancer Research</i> 2016; 22(10): 2435–2444.	CO.17
2016	62	McLachlan SA, Fisher RJ, Zalberg J, Solomon M, Burmeister B, Goldstein D, Leong T, Ackland SP, McKendrick J, McClure B, Mackay J, Ngan SY. The impact on health-related quality of life in the first 12 months: A randomised comparison of preoperative short- course radiation versus long-course chemoradiation for T3 rectal cancer (Trans-Tasman Radiation Oncology Group Trial 01.04). <i>European Journal of Cancer</i> 2016; 55: 15–26.	TROG 01.04
2016	63	Pavakis N, Sjoquist KM, Martin AJ, Tsobanis E, Yip S, Kang YK, Bang YJ, Alcindor T, O'Callaghan CJ, Burnell MJ, Tebbutt NC, Rha SY, Lee J, Cho JY, Lipton LR, Wong M, Strickland A, Kim JW, Zalberg JR, Simes J, Goldstein D. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo- controlled phase II trial. <i>Journal of Clinical Oncology</i> 2016; 34(23): 2728-2735.	INTEGRATE
2016	64	Price TJ, Thavaneswaran S, Burge M, Segelov E, Haller DG, Punt CJ, Arnold D, Karapetis CS, Tebbutt NC, Pavakis N, Gibbs P, Shapiro JD. Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015. <i>Expert Review of Anticancer Therapy</i> 2016; 16(5): 557–571.	Review
2016	65	Schofield PE, Stockler MR, Zannino D, Tebbutt NC, Price TJ, Simes RJ, Wong N, Pavakis N, Ransom D, Moylan E, Underhill C, Wyld D, Burns I, Ward R, Wilcken N, Jefford M. Hope, optimism and survival in a randomised trial of chemotherapy for metastatic colorectal cancer. <i>Supportive Care in Cancer</i> 2016; 24(1): 401–408.	MAX
2016	66	Segelov E, Thavaneswaran S, Waring PM, Desai J, Robledo KP, GebSKI VJ, Elez E, Nott LM, Karapetis CS, Lunke S, Chantrill LA, Pavakis N, Khasraw M, Underhill C, Ciardiello F, Jefford M, Wasan H, Haydon A, Price TJ, van Hazel G, Wilson K, Simes J, Shapiro JD. Response to cetuximab with or without irinotecan in patients with refractory metastatic colorectal cancer harboring the KRAS G13D mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study. <i>Journal of Clinical Oncology</i> 2016; 34(19): 2258–2264.	ICECREAM
2016	67	Segelov E, Waring P, Desai J, Wilson K, GebSKI V, Thavaneswaran S, Elez E, Underhill C, Pavakis N, Chantrill L, Nott L, Jefford M, Khasraw M, Day F, Wasan H, Ciardiello F, Karapetis C, Joubert W, van Hazel G, Haydon A, Price T, Tebpar S, Tebbutt N, Shapiro J. ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours. <i>BMC Cancer</i> 2016; 16: 339.	ICECREAM
2016	68	Tebbutt NC, Price TJ, Ferraro DA, Wong N, Veillard AS, Hall M, Sjoquist KM, Pavakis N, Strickland A, Varma SC, Cooray P, Young R, Underhill C, Shannon JA, Ganju V, GebSKI V. Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial. <i>British Journal of Cancer</i> 2016; 114(5): 505-509.	ATTAX3
2016	69	Thavaneswaran S, Price TJ. Optimal therapy for resectable rectal cancer. <i>Expert Review of Anticancer Therapy</i> 2016; 16(3): 285–302.	Review
2016	70	Vickers MM, Lee C, Tu D, Wheatley-Price P, Parulekar W, Brundage MD, Moore MJ, Au H, O'Callaghan CJ, Jonker DJ, Ringash J, Goldstein D. Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3. <i>Pancreatology</i> 2016; 16(6): 1106-1112.	PA.3
2015	71	Brule SY, Jonker DJ, Karapetis CS, O'Callaghan CJ, Moore MJ, Wong R, Tebbutt NC, Underhill C, Yip D, Zalberg JR, Tu D, Goodwin RA. Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. <i>European Journal of Cancer</i> 2015; 51(11): 1405-1414.	CO.17
2015	72	Casali PG, Le Cesne A, Poveda Velasco A, Kotasek D, Rutkowski P, Hohenberger P, Fumagalli E, Judson IR, Italiano A, Gelderblom H, Adenis A, Hartmann JT, Duffaud F, Goldstein D, Broto JM, Gronchi A, Dei Tos AP, Marréaud S, van der Graaf WTA, Zalberg JR, Litière S, Blay J-Y. Time to definitive failure to the first tyrosine kinase inhibitor in localized GI stromal tumors treated with imatinib as an adjuvant: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group intergroup randomized trial in collaboration with the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. <i>Journal of Clinical Oncology</i> 2015; 33(36): 4276–4283.	EORTC 62024
2015	73	Chan DL, Pavakis N, Shapiro J, Price TJ, Karapetis CS, Tebbutt NC, Segelov E. Does the chemotherapy backbone impact on the efficacy of targeted agents in metastatic colorectal cancer? A systematic review and meta-analysis of the literature [correction 10(9):e0138916. <i>PLoS ONE</i> 2015; 10(8): e0135599.	Review
2015	74	Chan MM, Sjoquist KM, Zalberg JR. Clinical utility of ramucirumab in advanced gastric cancer. <i>Biologics</i> 2015; 9: 93–105.	Review

YEAR	NO.	MANUSCRIPT	TRIAL
2015	75	Chandrasegaram MD, Goldstein D, Simes J, GebSKI V, Kench JG, Gill AJ, Samra JS, Merrett ND, Richardson AJ, Barbour AP. Meta-analysis of radical resection rates and margin assessment in pancreatic cancer. <i>British Journal of Surgery</i> 2015; 102(12): 1459–1472.	Review
2015	76	Chantrill LA, Nagrial AM, Watson C, Johns AL, Martyn-Smith M, Simpson S, Mead S, Jones MD, Samra JS, Gill AJ, Watson N, Chin VT, Humphris JL, Chou A, Brown B, Morey A, Pajic M, Grimmond SM, Chang DK, Thomas D, Sebastian L, Sjoquist K, Yip S, Pavlakis N, Asghari R, Harvey S, Grimison P, Simes J, Biankin AV. Precision medicine for advanced pancreas cancer: the Individualized Molecular Pancreatic Cancer Therapy (IMPACT) trial. <i>Clinical Cancer Research</i> 2015; 21(9): 2029-2037.	IMPACT
2015	77	Lee CK, Goldstein D, Gibbs E, Joensuu H, Zalberg J, Verweij J, Casali PG, Maki RG, Cioffi A, McArthur G, Lord SJ, Yip D, Kanjanapan Y, Rutkowski P. Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib. <i>European Journal of Cancer</i> 2015; 51(7): 852-860.	EORTC 62005
2015	78	Leong T, Smithers BM, Michael M, GebSKI V, Boussoutias A, Miller D, Simes J, Zalberg J, Hausterman K, Lordick F, Schuhmacher C, Swallow C, Darling G, Wong R. TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG). <i>BMC Cancer</i> 2015; 15: 532.	TOPGEAR
2015	79	Nagrial AM, Chin VT, Sjoquist KM, Pajic M, Horvath LG, Biankin AV, Yip D. Second-line treatment in inoperable pancreatic adenocarcinoma: a systematic review and synthesis of all clinical trials. <i>Critical Reviews in Oncology/Hematology</i> 2015; 96(3): 483–497.	Review
2015	80	Price TJ, Bruhn MA, Lee CK, Hardingham JE, Townsend AR, Mann K, J. S, Weickhardt A, Wrin JW, Wilson K, GebSKI V, Van Hazel G, Robinson B, Cunningham D, Tebbutt NC. Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the Phase III AGITG MAX involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer. <i>British Journal of Cancer</i> 2015; 112: 963-970.	MAX
2015	81	Roohullah A, Wong HLS, K.M., Gibbs P, Field K, Tran B, Shapiro J, McKendrick J, Yip D, Nott L, GebSKI V, Ng W, Chua W, Price T, Tebbutt N, Chantrill L. Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab. <i>World Journal of Gastroenterology</i> 2015; 21(17): 5352-5358.	MAX
2015	82	Sjoquist KM, Zalberg JR. Gastric cancer: past progress and present challenges [editorial]. <i>Gastric Cancer</i> 2015; 18(2): 205-209.	Review
2015	83	Stevenson AR, Solomon MJ, Lumley JW, Hewett P, Clouston AD, GebSKI VJ, Davies L, Wilson K, Hague W, Simes J. Effect of laparoscopic-assisted resection vs open resection on pathological outcomes in rectal cancer: the ALaCaRT randomized clinical trial. <i>JAMA</i> 2015; 314(13): 1356–1363.	A La CaRT
2015	84	Tanis E, Julie C, Emile JF, Mauer M, Nordlinger B, Aust D, Roth A, Lutz MP, Gruenberger T, Wrba F, Sorbye H, Bechstein W, Schlag P, Fisseler A, Ruers T. Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983. <i>European Journal of Cancer</i> 2015; 51(17): 2708–2717.	EORTC 40983
2015	85	Weickhardt AJ, Williams DS, Lee CK, Chionh F, Simes J, Murone C, Wilson K, Parry MM, Asadi K, Scott AM, Punt CJ, Nagtegaal ID, Price TJ, Mariadason JM, Tebbutt NC. Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer. <i>British Journal of Cancer</i> 2015; 113(1): 37–45.	MAX
2014	86	Bruhn MA, Townsend AR, Lee CK, Shivasami A, Price TJ, Wrin J, Arentz G, Tebbutt NC, Hocking C, Cunningham D, Hardingham JE, on behalf of the BHI in collaboration with AGITG. Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer. <i>International Journal of Cancer</i> 2014; 135(3): 731–741.	MAX
2014	87	Carter HE, Zannino D, Simes RJ, Schofield DJ, Howard K, Zalberg JR, Price TJ, Tebbutt NC. The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: results from the Australasian phase III MAX study. <i>European Journal of Cancer</i> 2014; 50(3): 535–543.	MAX
2014	88	Ferraro D, Zalberg J. Regorafenib in gastrointestinal stromal tumors: clinical evidence and place in therapy. <i>Therapeutic Advances in Medical Oncology</i> 2014; 6(5): 222–228.	Review
2014	89	Greenhalf W, Ghaneh P, Neoptolemos JP, Palmer DH, Cox TF, Lamb RF, Garner E, Campbell F, Mackey JR, Costello E, Moore MJ, Valle JW, McDonald AC, Carter R, Tebbutt NC, Goldstein D, Shannon J, Dervenis C, Glimelius B, Deakin M, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthony A, Halloran CM, Mayerle J, Oláh A, Jackson R, Rawcliffe CL, Scarpe A, Bassi C, Büchler MW, and for the European Study Group for Pancreatic Cancer. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. <i>Journal of the National Cancer Institute</i> 2014; 106(1): djt347.	ESPAC-3
2014	90	Hocking C, Hardingham J, Broadbridge V, Townsend AR, Tebbutt N, Cooper J, Ruzskiewicz A, Lee C, Price TJ. Can we accurately report PTEN status in advanced colorectal cancer? <i>BMC Cancer</i> 2014; 14: 128.	MAX
2014	91	Hohenberger P, Bonvalot S, Litiere S, Rutkowski P, van Coevorden F, Meeus P, Marréaud S, Raventos VA, Kotasek D, Padbury R, Van der Graaf W, Gronchi A. Surgical resection of metastatic GIST on imatinib delays recurrence and death: results of a cross-match comparison in the EORTC intergroup study 62005, aimed at assessing the clinical activity of imatinib at two dose levels in patients with unresectable or metastatic GIST <i>Connective Tissue Oncology Society</i> ; 15–18 Oct 2014; Berlin.	EORTC 62005
2014	92	Jonker D, Karapetis C, Harbison C, O'Callaghan C, Tu D, Simes R, Malone D, Langer C, Tebbutt N, Price T, Shapiro J, Siu L, Wong R, Bjarnason G, Moore M, Zalberg J, Khambata-Ford S. Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer. <i>British Journal of Cancer</i> 2014; 110(3): 648–55.	CO.17
2014	93	Karapetis CS, Jonker D, Daneshmand M, Hanson JE, O'Callaghan CJ, Marginean C, Zalberg JR, Simes J, Moore MJ, Tebbutt NC, Price TJ, Shapiro JD, Pavlakis N, Gibbs P, Van Hazel GA, Lee U, Haq R, Virk S, Tu D, Lorimer IA. PIK3CA, BRAF and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer—results from NCIC CTG/AGITG CO.17. <i>Clinical Cancer Research</i> 2014; 20(3): 744–753.	CO.17
2014	94	Price TJ, Segelov E, Burge M, Haller DG, Tebbutt NC, Karapetis CS, Punt CJ, Pavlakis N, Arnold D, Gibbs P, Shapiro JD. Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013. <i>Expert Review of Anticancer Therapy</i> 2014; 14(12): 1477–1493.	Review
2014	95	Ransom D, Wilson K, Fournier M, Simes RJ, GebSKI V, Yip D, Tebbutt N, Karapetis CS, Ferry D, Gordon S, Price TJ. Final results of Australasian Gastro-Intestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines. <i>Annals of Oncology</i> 2014; 25(1): 117–121. 13.	ARCTIC

YEAR	NO.	MANUSCRIPT	TRIAL
2014	96	Ringash J, Au HJ, Siu LL, Shapiro JD, Jonker DJ, Zalberg JR, Moore MJ, Strickland A, Kotb R, Jeffery M, Alcindor T, Ng S, Salim M, Sabesan S, Easaw JC, Shannon J, El-Tahche F, Walters I, Tu D, O'Callaghan CJ, NCIC Clinical Trials Group, Australasian Gastrointestinal Trials Group. Quality of life in patients with K-RAS wild-type colorectal cancer: the CO.20 phase 3 randomized trial. <i>Cancer</i> 2014; 120(2): 181–189.	CO.20
2014	97	Rosmarin D, Palles C, Church D, Domingo E, Jones A, Johnstone E, Wang H, Love S, Julier P, Scudder C, Nicholson G, Gonzalez-Neira A, Martin M, Sargent DJ, Green E, McLeod H, Zanger UM, Schwag M, Seymour MT, Thompson L, Lacas B, Boige V, Ribelles N, Afzal S, Enghusen H, Etienne-Grimaldi MC, Milano G, Wadelius M, Glimelius B, Garmo H, Gusella M, Lecomte T, Laurent-Puig, Martinez-Balibrea E, Sharma R, Garcia-Foncillas J, Kleibl Z, Morel A, Pignon JP, Midgley RS, Kerr D, Tomlinson I. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. <i>Journal of Clinical Oncology</i> 2014; 32(10): 1031–1039.	QUASAR 2
2014	98	Sommeijer DW, Karapetis CS, Zalberg JR, Tu D, Jonker DJ, Simes J, Tebbutt N, Yip D, Price TJ, O'Callaghan CJ. The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17. <i>Acta Oncologica</i> 2014; 53(7): 877–884.	CO.17
2014	99	Valle JW, Palmer D, Jackson R, Cox T, Neoptolemos JP, Ghaneh P, Rawcliffe CL, Bassi C, Stocken DD, Cunningham D, O'Reilly D, Goldstein D, Robinson BA, Karapetis C, Scarfe A, Lacaine F, Sand J, Izbicki JR, Mayerle J, Derveniz C, Oláh A, Butturini G, Lind PA, Middleton MR, Anthony A, Sumpter K, Carter R, Büchler MW. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. <i>Journal of Clinical Oncology</i> 2014; 32(6): 504–512.	ESPAC-3
2013	100	Yothers G, O'Connell MJ, Lee M, Lopatin M, Clark-Langone KM, Millward C, Paik S, Sharif S, Shak S, Wolmark N. Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin. <i>J Clin Oncol.</i> 2013 Dec 20;31(36):4512-9. doi: 10.1200/JCO.2012.47.3116. Epub 2013 Nov 12. Erratum in: <i>J Clin Oncol.</i> 2014 Mar 10;32(8):866. PMID: 24220557; PMCID: PMC3871512.	C-07
2013	101	Harbison CT, Horak CE, Ledezine JM, Mukhopadhyay P, Malone DP, O'Callaghan C, Jonker DJ, Karapetis CS, Khambata-Ford S, Gustafson N, Trifan OC, Chang SC, Ravetto P, Green GA 4th. Validation of companion diagnostic for detection of mutations in codons 12 and 13 of the KRAS gene in patients with metastatic colorectal cancer: analysis of the NCIC CTG CO.17 trial. <i>Archives of Pathology & Laboratory Medicine</i> 2013; 137(6): 820–827.2	CO.17
2013	102	Hurwitz HI, Tebbutt NC, Kabbinavar F, Giantonio BJ, Guane ZZ, Michell L, Waterkamp D, Tabernerog J. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. <i>Oncologist</i> 2013; 18(9): 1004– 1012.	MAX
2013	103	Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Mauer M, Tanis E, Van Cutsem E, Scheithauer W, Gruenberger T, for the EORTC Gastro-Intestinal Tract Cancer Group, Cancer Research UK Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO), Australasian Gastro- Intestinal Trials Group (AGITG), Fédération Francophone de Cancérologie Digestive (FFCD). Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> 2013; 14(12): 1208–1215.	EORTC 40983
2013	104	Price T, Hardingham J, Lee C, Townsend A, Wrin J, Wilson K, Weickhardt A, Simes R, Murone C, Tebbutt N. Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer receiving bevacizumab. <i>Cancer Medicine</i> 2013; 2(3): 277–285.	MAX
2013	105	Bidard FC, Huguet F, Louvet C, Mineur L, Bouché O, Chibaudel B, Artru P, Desseigne F, Bachet JB, Mathiot C, Pierga JY, Hammel P. Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial. <i>Ann Oncol.</i> 2013 Aug;24(8):2057-61. doi: 10.1093/annonc/mdt176. Epub 2013 May 14. PMID: 23676420.	LAP-07
2013	106	Siu L, Shapiro J, Jonker D, Karapetis C, Zalberg J, Simes J, Couture F, Moore M, Price T, Siddiqui J, Nott L, Charpentier D, Liauw W, Sawyer M, Jefford M, Magoski N, Haydon A, Walters I, Ringash J, Tu D, O'Callaghan C. Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 trial. <i>Journal of Clinical Oncology</i> ; 31(19): 2477-2484.	CO.20
2013	107	Sjoquist KM, Zalberg JR. Clinical trials: advancing national cancer care. <i>Cancer Forum</i> 2013; 37(1): 80–87.	Review
2013	108	Tebbutt NC, Parry MM, Zannino D, Strickland AH, Van Hazel GA, Pavlakis N, Ganju V, Mellor D, Dobrovic A, Gebbski VJ, on behalf of the Australasian Gastro-Intestinal Trials Group (AGITG). Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial. <i>British Journal of Cancer</i> 2013; 108(4): 771–774.	ATTAX2
2013	109	Vickers MM, Karapetis CS, Tu D, O'Callaghan CJ, Price TJ, Tebbutt NC, Van Hazel G, Shapiro JD, Pavlakis N, Gibbs P, Blondal J, Lee U, Meharchand JM, Burkes RL, Rubin SH, Simes J, Zalberg JR, Moore MJ, Zhu L, Jonker DJ. Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17. <i>Annals of Oncology</i> 2013; 24(4): 953–960.	CO.17
2012	110	Clarke SJ, Yip S, Brown C, van Hazel GA, Ransom DT, Goldstein D, Jeffrey GM, Tebbutt NC, Buck M, Lowenthal RM, Boland A, Gebbski V, Zalberg J, Simes RJ. Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected]. <i>European Journal of Cancer</i> 2011; 47(12): 1826–1836. 1.	DaVINCI
2012	111	Dear RF, Barratt AL, Evans A, Simes J, Newsom J, Kent D, Crossing S, Holliday C, Segelov E, Hruby G, Tattersall MH. Identifying and prioritising gaps in colorectal cancer trials research in Australia. <i>Medical Journal of Australia</i> 2012; 197(9): 507–511.	Review
2012	112	Goldstein D, Spry N, Cummins MM, Brown C, van Hazel GA, Carroll S, Selva-Nayagam S, Borg M, Ackland SP, Wratten C, Shapiro J, Porter, IWT, Hruby G, Horvath L, Bydder S, Undercill C, Harvey J, Gebbski VJ; on behalf of the Australasian Gastro-Intestinal Trials Group. The GOFURTO Study: AGITG phase II study of fixed dose rate gemcitabine–oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer. <i>British Journal of Cancer</i> 2012; 106(1): 61–69.	Gofurto

YEAR	NO.	MANUSCRIPT	TRIAL
2012	113	Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, Carter R, Tebbutt NC, Dervenis C, Smith D, Glimelius B, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthony A, Ghaneh P, Halloran CM, Lerch MM, Oláh A, Rawcliffe CL, Verbeke CS, Campbell F, Büchler MW, European Study Group for Pancreatic Cancer. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. <i>JAMA</i> 2012; 308(2): 147–156.	ESPAC-3
2012	114	Ng M, Leong T, Chander S, Chu J, Kneebone A, Carroll S, Wiltshire K, Ngan S, Kachnic L. Australasian Gastrointestinal Trials Group (AGITG) contouring atlas and planning guidelines for intensity- modulated radiotherapy in anal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> 2012; 83(5): 1455–1462.	Review
2012	115	Ngan SY, Burmeister B, Fisher RJ, Solomon M, Goldstein D, Joseph D, Ackland SP, Schache D, McClure B, McLachlan SA, McKendrick J, Leong T, Hartoepanu C, Zalcborg J, Mackay J. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. <i>Journal of Clinical Oncology</i> 2012; 30(31): 3827–3833. A published correction appears in <i>Journal of Clinical Oncology</i> 2013;31(3):399.	TROG 01.04
2012	116	Price TJ, Zannino D, Wilson K, Simes J, Cassidy J, Van Hazel GA, Robinson BA, Broad A, Ganju V, Ackland SP, Tebbutt NC. Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of capecitabine, bevacizumab and mitomycin C. <i>Annals of Oncology</i> 2012; 23(6): 1353–1536.	MAX
2012	117	Sorbye H, Mauer M, Gruenberger T, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch- Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Van Cutsem E, Scheithauer W, Lutz MP, Nordlinger B; EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK (CRUK); Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro- Intestinal Trials Group (AGITG); Fédération Francophone de Cancérologie Digestive (FFCD). Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). <i>Annals of Surgery</i> 2012; 255(3): 534–539.	EORTC 40983
2012	118	Vickers MM, Powell ED, Asmis TR, Jonker DJ, Hilton JF, O'Callaghan CJ, Tu D, Parulekar W, Moore MJ. Comorbidity, age and overall survival in patients with advanced pancreatic cancer—results from NCIC CTG PA.3: a phase III trial of gemcitabine plus erlotinib or placebo. <i>European Journal of Cancer</i> 2012; 48(10): 1434–1442.	PA.3
2011	119	Asmis TR, Powell E, Karapetis CS, Jonker DJ, Tu D, Jeffery M, Pavlakis N, Gibbs P, Zhu L, Dueck DA, Whittom R, Langer C, O'Callaghan CJ. Comorbidity, age and overall survival in cetuximab- treated patients with advanced colorectal cancer (ACRC)—results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care. <i>Annals of Oncology</i> 2011; 22(1): 118–126.	CO.17
2011	120	Goldstein D, Gainford MC, Brown C, Tebbutt N, Ackland SP, van Hazel G, Jefford M, Abdi E, Selva-Nayagam S, GebSKI V, Miller D, Shannon J. Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. <i>Cancer Chemotherapy and Pharmacology</i> 2011; 67(3): 519–525.	ABC
2011	121	Price TJ, Hardingham JE, Lee CK, Weickhardt A, Townsend AR, Wrin JW, Chua A, Shivasami A, Cummins MM, Murone C, Tebbutt NC. Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer. <i>Journal of Clinical Oncology</i> 2011; 29(19): 2675–2682.	MAX
2011	122	Sjoquist K, Burmeister B, Smithers BM, Zalcborg JR, Simes J, Barbour A, GebSKI V; on behalf of the Australasian Gastro-Intestinal Trials Group(AGITG). Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. <i>Lancet Oncology</i> 2011; 12(7): 681–692.	IG9401
2011	123	Tebbutt NC, Murphy F, Zannino D, Wilson K, Cummins MM, Abdi E, Strickland AH, Lowenthal RM, Marx G, Karapetis C, Shannon J, Goldstein D, Nayagam SS, Blum R, Chantrill L, Simes RJ, Price TJ; on behalf of the Australasian Gastro-Intestinal Trials Group (AGITG). Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. <i>Annals of Oncology</i> 2011; 22(8): 1834–1838.	MAX
2011	124	Yothers G, O'Connell M, Allegra C, Kuebler J, Colangelo L, Petrelli N, Wolmark N. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. <i>Journal of Clinical Oncology</i> 2011; 29(28): 3768-3774.	C-07
2010	125	da Cunha Santos G, Dhani N, Tu D, Chin K, Ludkovski O, Kamel-Reid S, Squire J, Parulekar W, Moore MJ, Tsao MS. Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3. <i>Cancer</i> . 2010 Dec 15;116(24):5599-607. doi: 10.1002/cncr.25393. Epub 2010 Sep 7. PMID: 20824720.	PA.3
2010	126	O'Connell MJ, Lavery I, Yothers G, Paik S, Clark-Langone KM, Lopatin M, Watson D, Baehner FL, Shak S, Baker J, Cowens JW, Wolmark N. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. <i>J Clin Oncol</i> . 2010 Sep 1;28(25):3937-44. doi: 10.1200/JCO.2010.28.9538. Epub 2010 Aug 2. PMID: 20679606; PMCID: PMC2940392.	C-06
2010	127	De Roock S, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, Van Cutsem E, O'Callaghan CJ, Khambata-Ford S, Zalcborg JR, Simes J, Karapetis CS, Bardelli A, Tejpar S. Association of Kras p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. <i>JAMA</i> 2010; 304(16): 1812–1820.	CO.17
2010	128	MetaGIST: Gastrointestinal Stromal Tumor Meta-Analysis Group, Verweij J, Blay J, Debiec-Rychter M, Demetri G, Heinrich M, Borden E, Blanke C, Crowley J, Rankin C, Casali P, Von Mehren M, Fletcher C, Fletcher J, Owzar K, Zalcborg J, Simes J, Bramwell V. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1640 patients. <i>Journal of Clinical Oncology</i> 2010; 28(7): 1247–1253.	EORTC 62005
2010	129	Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, Wente MN, Izbicki JR, Friess H, Lerch MM, Dervenis C, Oláh A, Butturini G, Doi R, Lind PA, Smith D, Valle JW, Palmer DH, Buckels JA, Thompson J, McKay CJ, Rawcliffe CL, Büchler, MW; for the European Study Group for Pancreatic Cancer. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. <i>JAMA</i> .2010; 304(10): 1073–1081.	ESPAC-3
2010	130	Tebbutt NC, Cummins MM, Sourjina T, Strickland AH, Van Hazel G, Ganju V, Gibbs D, Stockler M, GebSKI V, Zalcborg J; on behalf of the Australasian Gastro-Intestinal Trials Group. Randomised, non- comparative phase II study of weekly docetaxel with cisplatin and 5- fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. <i>British Journal of Cancer</i> 2010; 102: 475–481.	ATTAX

YEAR	NO.	MANUSCRIPT	TRIAL
2010	131	Tebbutt NC, Wilson K, GebSKI VJ, Cummins MM, Zannino D, van Hazel GA, Robinson B, Broad A, Ganju V, Ackland SP, Forgeson G, Cunningham D, Saunders MP, Stockler MR, Chua YJ, Zalberg JR, Simes RJ, Price TJ. Capecitabine, bevacizumab and mitomycin C in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group randomised phase III MAX study. <i>Journal of Clinical Oncology</i> 2010; 28(19): 3191–3198.	MAX
2009	132	Au HJ, Karapetis CS, O'Callaghan CJ, Tu D, Moore MJ, Zalberg J, Kennecke H, Shapiro JD, Koski S, Pavlakis N, Charpentier D, Wyld D, Jefford M, Knight GJ, Magoski NM, Brundage MD, Jonker DJ. Health-related quality of life in advanced colorectal cancer patients treated with cetuximab: overall and Kras-specific results of the NCIC CTG and AGITG CO.17 trial. <i>Journal of Clinical Oncology</i> 2009; 27(11): 1822–1828.	CO.17
2009	133	Chua W, Goldstein D, Lee C, Dhillon H, Michael M, Mitchell P, Clarke S, Iacopetta B. Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. <i>British Journal of Cancer</i> 2009; 101(6): 998–1004.	
2009	134	Hicks S, James R, Wong N, Tebbutt NC, Wilson S. A case study comparison of ethical review systems for multicentre clinical trials in Australia. <i>Medical Journal of Australia</i> 2009; 191(5): 280–282.	MAX CO.20
2009	135	Le Cesne A, Van Glabbeke M, Verweij J, Casali PG, Findlay M, Reichardt P, Issels R, Judson I, Schoffski P, Leyvraz S, Bui B, Hogendoorn PC, Sciot R, Blay JY. Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the Intergroup EORTC-ISG-AGITG phase III trial. <i>Journal of Clinical Oncology</i> 2009;27(24): 3969–3974.	EORTC 62005
2009	136	Michael M, Price T, Ngan SY, Ganju V, Strickland AH, Muller A, Khamly K, Milner AD, Dilulio J, Matera A, Zalberg JR, Leong T. A phase I trial of capecitabine + gemcitabine with radical radiation for locally advanced pancreatic cancer. <i>British Journal of Cancer</i> 2009; 100 (1): 37–43.	
2009	137	Mittmann N, Au HJ, Tu D, O'Callaghan CJ, Isogai PK, Karapetis CS, Zalberg JR, Evans WK, Moore MJ, Siddiqui J, Findlay B, Colwell B, Simes J, Gibbs P, Links M, Tebbutt NC, Jonker DJ; Working Group on Economic Analysis of the National Cancer Institute of Canada Clinical Trials Group–Australasian Gastrointestinal Interest Group. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial. <i>Journal of the National Cancer Institute</i> 2009; 101(17): 1182–1192.	CO.17
2009	138	Neoptolemos JP, Stocken DD, Tudur Smith C, Bassi C, Ghaneh P, Owen E, Moore M, Padbury R, Doi R, Smith D, Büchler MW. Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials. <i>British Journal of Cancer</i> 2009; 100(2): 246–250.	ESPAC 1 ESPAC 3
2009	139	Romeo S, Debiec-Rychter M, Van Glabbeke M, Van Paassen H, Comite P, Van Eijk R, Oosting J, Verweij J, Terrier P, Schneider U, Sciot R, Blay J, Hogendoorn P, on behalf of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Cell cycle/apoptosis molecule expression correlates with imatinib response in patients with advanced gastrointestinal stromal tumors. <i>Clinical Cancer Research</i> 2009; 15(12): 4191-4198.	EORTC 62005
2008	140	Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalberg JR. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. <i>New England Journal of Medicine</i> 2008; 359(17): 1757–1765.	CO.17
2008	141	Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Praet M, Bethe U, Van Cutsem E, Scheithauer W, Gruenberger T; EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK; Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro- Intestinal Trials Group (AGITG); Fédération Francophone de Cancérologie Digestive (FFCD). Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. <i>Lancet</i> 2008; 371(9617): 1007–1016.	EORTC 40983
2008	142	Nowak AK, Cebon J, Hargreaves C, Dhillon H, Findlay M, GebSKI V, Stockler MR. Assessment of health-related quality of life and patient benefit as outcome measures for clinical trials in hepatocellular carcinoma. <i>Asia-Pacific Journal of Clinical Oncology</i> 2008; 4: 55-67.	AG0001H
2008	143	Sciot R, Debiec-Rychter M, Daugaard S, Fisher C, Collin F, Van Glabbeke M, Verweij J, Blay J-Y, Hogendoorn, PCW; on behalf of the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group and the Australian Trials Group. Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumors. An analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate. <i>European Journal of Cancer</i> 2008; 44: 1855–1860.	EORTC 62005
2008	144	Van Cutsem E, Dicato M, Haustermans K, Arber N, Bosset J-F, Cunningham D, De Gramont A, Diaz-Rubio E, Ducreux M, Goldberg R, Glynne-Jones R, Haller D, Kang Y-K, Kerr D, Labianca R, Minsky BD, Moore M, Nordlinger B, Rougier P, Scheithauer W, Schmoll H-J, Sobrero A, Taberero J, Tempero M, Van de Velde C, Zalberg J. The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007. <i>Annals of Oncology</i> 2008; 19(suppl 6): vi1-vi8.	Review
2007	145	Findlay M, Storey D, GebSKI V, Hargreaves C, Cullingford G, Boyer M, Trotter J, Archer S, Davidson A, Johnston P, Yuen J, Dhillon H, Della-Fiorentina S, Richardson G, Truskett P, Goldstein D; on behalf of the AGITG. A pilot study of preoperative and postoperative chemotherapy in patients with operable gastric cancer: Australasian Gastrointestinal Trials Group Study 9601. <i>Australian and New Zealand Journal of Surgery</i> 2007; 77(4): 247–252.	AG9601
2007	146	GebSKI V, Burmeister B, Smithers MB, Foo K, Zalberg J, Simes J. Meta-analysis of the survival benefits from preoperative chemoradiation therapy and chemotherapy in oesophageal carcinoma. <i>Lancet Oncology</i> 2007; 8: 226–234.	IG9401
2007	147	Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C, Moore MJ. Cetuximab for the treatment of colorectal cancer. <i>New England Journal of Medicine</i> 2007; 357(20): 2040–2048.	CO.17
2007	148	Kopec JA, Yothers G, Ganz PA, Land SR, Cecchini RS, Wieand HS, Lembersky BC, Wolmark N. Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06. <i>Journal of Clinical Oncology</i> 2007; 25(4): 424–430.	C-06
2007	149	Kuebler JP, Colangelo L, O'Connell MJ, Smith RE, Yothers G, Begovic M, Robinson B, Seay TE, Wolmark N. Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin: a prospective analysis. <i>Cancer</i> 2007; 110(9): 1945–1950.	C-07
2007	150	Kuebler JP, Wieand S, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. <i>Journal of Clinical Oncology</i> 2007; 25(16): 2198–2204.	C-07

YEAR	NO.	MANUSCRIPT	TRIAL
2007	151	Land SR, Kopec JA, Cecchini RS, Ganz PA, Wieand HS, Colangelo LH, Murphy K, Kuebler JP, Seay TE, Needles BM, Bearden JD 3rd, Colman LK, Lanier KS, Pajon ER Jr, Cella D, Smith RE, O'Connell MJ, Costantino JP, Wolmark N. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. <i>Journal of Clinical Oncology</i> 2007; 25(16): 2205–2211.	C-07
2007	152	Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. <i>Journal of Clinical Oncology</i> 2007; 25(15): 1960–1966.	PA-13
2007	153	Verweij J, Casali PG, Kotasek D, LeCesne A, Reichard P, Judson IR, Issels R, Van Oosterom AT, Van Glabbeke M, Blay J-Y. Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005. <i>European Journal of Cancer</i> 2007; 43: 974–978.	EORTC 62005
2006	154	Cebon J, Hargreaves C, Stockler M, Nowak A, Dhillon H, Dickman B, GebSKI V; Australasian Gastro-Intestinal Trials Group (AGITG) AG0001H Investigators. Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. <i>British Journal of Cancer</i> 2006; 95(7): 853–861.	AG0001H
2006	155	Cunningham D, Allum W, Stenning S, Thompson J, Van de Velde C, Nicolson M, Scarffe J, Lofts F, Falk S, Iveson T, Smith D, Langley R, Verma M, Weeden S, Chua Y, for the MAGIC trial participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. <i>New England Journal of Medicine</i> 2007; 355(1): 11-20.	MAGIC
2006	156	Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom AT, Blay JY, Leyvraz S, Stul M, Casali PG, Zalcbberg J, Verweij J, Van Glabbeke M, Hagemeyer A, Judson I; On behalf of the EORTC Soft Tissue and Bone Sarcoma Group, The Italian Sarcoma Group and the Australasian Gastro-Intestinal Trials Group. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. <i>European Journal of Cancer</i> 2006; 42(8): 1093–103.	EORTC 62005
2006	157	Lembersky BC, Wieand HS, Petrelli NJ, O'Connell MJ, Colangelo LH, Smith RE, Seay TE, Giguere JK, Marshall ME, Jacobs AD, Colman LK, Soran A, Yothers G, Wolmark N. Oral Uracil and Tegafur Plus Leucovorin Compared with Intravenous Fluorouracil and Leucovorin in Stage II and III Carcinoma of the Colon: Results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. <i>Journal of Clinical Oncology</i> 2006; 24(13): 2059-64.	C-06
2006	158	Tamborini E, Bonadiman L, Greco A, Albertini V, Negri T, Gronchi A, Bertulli R, Colecchia M, Casali P, Pierotti M, Pilotti S. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. <i>Gastroenterology</i> 2004; 127(1): 294–299.	EORTC 62005
2006	159	Van Glabbeke M, Verweij J, Casali PG, Simes J, Cesne AL, Reichardt P, Issels R, Judson IR, van Oosterom AT, Blay JY. Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC- IS G-AGITG). <i>European Journal of Cancer</i> 2006; 42(14): 2277–2285.	EORTC 62005
2005	160	Ackland SP, Jones M, Tu D, Simes J, Yuen J, Sargeant A-M, Dhillon H, Goldberg RM, Abdi E, Shepherd L, Moore MJ. A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer. <i>British Journal of Cancer</i> 2005; 93: 1235–1243.	AG9401
2005	161	Burmeister BH, Smithers BM, GebSKI V, Fitzgerald L, Simes RJ, Devitt P, Ackland S, Gotley DC, Joseph D, Millar J, North J, Walpole ET, Denham JW, for the Trans-Tasman Radiation Oncology Group (TROG) and the Australasian Gastro-Intestinal Trials Group (AGITG) Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. <i>Lancet Oncology</i> 2005; 6(9): 659–668.	IG9401
2005	162	Goldstein D, Tan B, Rossleigh M, Haindl W, Walker B, Dixon J. Gastrointestinal stromal tumours: correlation of F-18-FDG gamma camera-based coincidence positron emission tomography with CT for the assessment of treatment response--an AGITG study. <i>Oncology</i> 2005; 69(4): 326-332.	EORTC 62005
2005	163	Van Glabbeke M, Verweij J, Casali P, Le Cesne A, Hohenberger P, Ray-Coquard I, Schlemmer M, van Oosterom A, Goldstein D, Sciot R, Hogendoorn P, Brown M, Bertulli R, Judson I. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group– Australasian Gastro-Intestinal Trials Group Study. <i>Journal of Clinical Oncology</i> 2005; 23(24): 5795-5804.	EORTC 62005
2005	164	Zalcbberg J, Verweij J, Casali P, Le Cesne A, Reichardt P, Blay J, Schlemmer M, Van Glabbeke M, Brown M, Judson I, EORTC Soft Tissue and Bone Sarcoma Group tISGAG-ITG. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. <i>European Journal of Cancer</i> 2005; 41(12): 1751-1757.	EORTC 62005
2004	165	Nowak A, Chow P, Findlay M. Systemic therapy for advanced hepatocellular carcinoma: a review. <i>European Journal of Cancer</i> 2004; 40(10): 1474-1484.	AG0001H
2004	166	Nowak A, Findlay M, Culjak G, Stockler M. Tamoxifen for hepatocellular carcinoma. <i>Cochrane Database of Systematic Reviews</i> 2004; (3): CD001024	AG0001H
2004	167	Verweij J, Casali P, Zalcbberg J, Le Cesne A, Reichardt P, Blay J-Y, Issels R, van Oosterom A, Hogendoorn P, van Glabbeke M, Judson I, Bertulli R, Judson I, for the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group and the Australian Gastro- intestinal trials group: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. <i>Lancet</i> 2004; 364: 1127–1134.	EORTC 62005
2002	168	Kemeny MM, Sudeshna A, Gray B, Macdonald JS, Smith T, Sigurdson LR, O'Dwyer PJ, Benson AB. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy—an intergroup study. <i>Journal of Clinical Oncology</i> 2002; 20(6): 1499–1505.	E9288
2001	169	Gray B, Van Hazel G, Hope M, Burton M, Moroz P, Anderson J, GebSKI V. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. <i>Annals of Oncology</i> 2001; 12(12): 1711- 1720.	AG9802
1996	170	Zalcbberg J, Siderov J, Simes J. The role of 5-fluorouracil dose in the adjuvant therapy of colorectal cancer. <i>Annals of Oncology</i> 1996; 7(1): 42-46.	Review